Frej Fyhrquist

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Björn Dahlöf, Richard B. Devereux, Sverre E. Kjeldsen et al. · The Lancet · 2002 · 5.4K citations

Medicine, Cardiology, Internal Medicine +13

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Lars Lindholm, Hans Ibsen, Björn Dahlöf et al. · The Lancet · 2002 · 1.6K citations

Medicine, Cardiology, Internal Medicine +15

Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients

Hans Ibsen, Michael Hecht Olsen, Kristian Wachtell et al. · Hypertension · 2005 · 564 citations

Medicine, Cardiology, Pharmacotherapy +15

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

Aud Høieggen, Michael H. Alderman, Sverre E. Kjeldsen et al. · Kidney International · 2004 · 476 citations

Medicine, Cardiology, Physiology +9

PLASMA ATRIAL NATRIURETIC PEPTIDE IN CARDIAC DISEASE AND DURING INFUSION IN HEALTHY VOLUNTEERS

Ilkka Tikkanen, Kaj Metsärinne, Frej Fyhrquist et al. · The Lancet · 1985 · 469 citations

Medicine, Cardiology, Pharmacology +5